STOCK TITAN
  1. Home
  2. Sec-filings
  3. PSTV
  4. [Form 4] PLUS THERAPEUTICS, INC. Insider Trading Activity

Plus Therapeutics (NASDAQ: PSTV) director gains 922 shares via RSU vesting

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Plus Therapeutics director Howard Clowes exercised restricted stock units into common shares as part of equity compensation. On this Form 4, he acquired 922 shares of Plus Therapeutics common stock through the conversion of restricted stock units at a stated price of $0.00 per share.

Following the transaction, Clowes directly holds 1,981 shares of common stock and 2,764 restricted stock units. Each RSU represents a contingent right to receive one common share, with vesting in four substantially equal quarterly installments beginning on July 1, 2026. This filing reflects routine equity incentive vesting rather than an open-market stock purchase or sale.

Positive

  • None.

Negative

  • None.
Insider Clowes Howard
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 922 $0.00 --
Exercise Common Stock 922 $0.00 --
Holdings After Transaction: Restricted Stock Units — 2,764 shares (Direct, null); Common Stock — 1,981 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Common shares acquired 922 shares Common Stock received via RSU exercise on July 1, 2026
Common shares held after 1,981 shares Direct Plus Therapeutics common stock holding after transaction
RSUs held after 2,764 RSUs Restricted Stock Units outstanding following the reported exercise
RSU-to-share ratio 1 RSU : 1 share Each RSU represents a contingent right to one common share
Exercise price $0.00 per share Stated price per share for RSU conversion to common stock
Restricted Stock Units financial
"Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
contingent right financial
"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clowes Howard
(Last)(First)(Middle)
C/O PLUS THERAPEUTICS INC.
6420 LEVIT GREEN BOULEVARD, SUITE 310
(Street)
HOUSTON TEXAS 77021
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026M922(2)A$0(1)1,981D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units$007/01/2026M922 (2) (2)Common Stock922$02,764D
Explanation of Responses:
1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.
2. Represents the vesting of an RSU grant which occurs in four substantially equal quarterly installments beginning on July 1, 2026.
Andrew Sims, as attorney-in-fact07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Plus Therapeutics (PSTV) disclose for Howard Clowes?

Plus Therapeutics director Howard Clowes exercised 922 restricted stock units into common stock. This derivative conversion increased his direct common share holdings and reflects equity compensation vesting, not an open-market stock purchase or sale.

How many Plus Therapeutics (PSTV) shares does Howard Clowes hold after this Form 4?

After the reported transaction, Howard Clowes directly holds 1,981 shares of Plus Therapeutics common stock. The filing also shows 2,764 restricted stock units outstanding, each representing a contingent right to receive one additional common share upon vesting.

What are the terms of the restricted stock units reported by Plus Therapeutics (PSTV)?

Each restricted stock unit represents a contingent right to receive one Plus Therapeutics common share. The RSU grant vests in four substantially equal quarterly installments beginning on July 1, 2026, aligning director compensation with the company’s longer-term performance.

Was the Plus Therapeutics (PSTV) insider transaction a market buy or sell?

The transaction was not a market buy or sell; it was an exercise or conversion of derivative securities. Howard Clowes received 922 common shares via restricted stock unit vesting at a stated price of $0.00 per share as part of his equity compensation.

How many restricted stock units does Howard Clowes have after this Plus Therapeutics (PSTV) filing?

After the transaction, Howard Clowes holds 2,764 restricted stock units. These RSUs convert into an equal number of Plus Therapeutics common shares as they vest in four substantially equal quarterly installments starting July 1, 2026.